Market Overview:
The global acquired orphan blood diseases therapeutics market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to factors such as increasing prevalence of blood diseases, rising demand for novel therapies and increasing number of clinical trials for orphan blood diseases. However, the high cost associated with orphan drugs is expected to restrain the growth of this market during the forecast period. Based on type, the global acquired orphan blood diseases therapeutics market is segmented into medication, bone marrow transplant (BMT), blood transfusion and immunotherapy. The medication segment accounted for majority share in 2017 and is projected to maintain its dominance during the forecast period. This can be attributed to rising demand for novel therapies and increasing number of clinical trials for orphan blood diseases.
Product Definition:
Acquired orphan blood diseases therapeutics are treatments for rare, usually inherited, blood disorders. They are important because they can improve the quality of life for people who have these diseases.
Medication:
Medication is the process through which a physician or a healthcare professional provides therapeutic treatment for an illness. Medications are available in various forms such as drugs, biologics, and monoclonal antibodies. The most common types of medications used to treat blood disorders include antibiotics and antifungals.
Bone Marrow Transplant:
Bone marrow transplant (BMT) is a procedure to replace damaged or diseased bone marrow with healthy donor bone marrow. It is used in the treatment of various blood diseases such as chronic granulomatous disease, polycythemia vera, and myelodysplastic syndrome. The market for BMT in acquired orphan blood diseases therapeutics has been segmented on the basis of product type and indication.
Application Insights:
The others application segment accounted for the largest revenue share in 2016 and is anticipated to witness significant growth during the forecast period. Other applications include research settings where acquired or orphaned blood diseases therapeutics are studied in vitro or in animal models. The medications application segment is expected to grow at a faster rate than other segments owing to its ability to treat multiple co-infections, such as HIV, hepatitis C and B viruses, and tuberculosis bacteria. Medications are generally expensive than other therapies; this factor will limit their use for treating common infections over the coming years. However, new drugs become available every year that can effectively treat various infections without causing severe side effects like medication does not exist yet for some common types of infection such as chickenpox or influenza A virus infection.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high adoption rate for novel therapeutics are some of the factors responsible for its large share. For instance, in February 2015, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a subsidiary of Fujifilm Holdings Corporation developed an immunotherapy treatment named as ATG-2 that targets multiple sclerosis (MS) symptoms such as fatigue and muscle spasms using acquired immune cells from donors worldwide.
Asia Pacific region is expected to grow at a lucrative rate over the forecast period owing to increasing disposable income levels coupled with growing healthcare awareness among people especially towards prevention of infectious diseases due to low cost compared to imported drugs.
Growth Factors:
- Increasing incidence of acquired orphan blood diseases
- Growing awareness about available treatments for acquired orphan blood diseases
- Rising demand for better and more effective therapies for acquired orphan blood diseases
- Technological advancements in the field of diagnostics and therapeutics for acquired orphan blood diseases 5. increasing funding from government and private organizations to support research and development activities in the field of Acquired Orphan Blood Diseases Therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Acquired Orphan Blood Diseases Therapeutics Market Research Report
By Type
Medication, Bone Marrow Transplant, Blood Transfusion, Immunotherapy
By Application
Hospitals, Clinics, Others
By Companies
Alexion Pharmaceuticals, Amgen, Celgene, Eli Lilly, Sanofi, GlaxoSmithKline, Cyclacel Pharmaceuticals, Onconova Therapeutics, Incyte, CTI BioPharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Acquired Orphan Blood Diseases Therapeutics Market Report Segments:
The global Acquired Orphan Blood Diseases Therapeutics market is segmented on the basis of:
Types
Medication, Bone Marrow Transplant, Blood Transfusion, Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alexion Pharmaceuticals
- Amgen
- Celgene
- Eli Lilly
- Sanofi
- GlaxoSmithKline
- Cyclacel Pharmaceuticals
- Onconova Therapeutics
- Incyte
- CTI BioPharma
Highlights of The Acquired Orphan Blood Diseases Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medication
- Bone Marrow Transplant
- Blood Transfusion
- Immunotherapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acquired Orphan Blood Diseases Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acquired or orphan blood diseases therapeutics are medications that are designed to treat rare blood disorders. These medications are often expensive and difficult to find, so they may only be available through a doctor's prescription.
Some of the major companies in the acquired orphan blood diseases therapeutics market are Alexion Pharmaceuticals, Amgen, Celgene, Eli Lilly, Sanofi, GlaxoSmithKline, Cyclacel Pharmaceuticals, Onconova Therapeutics, Incyte, CTI BioPharma.
The acquired orphan blood diseases therapeutics market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acquired Orphan Blood Diseases Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acquired Orphan Blood Diseases Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acquired Orphan Blood Diseases Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acquired Orphan Blood Diseases Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acquired Orphan Blood Diseases Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Acquired Orphan Blood Diseases Therapeutics Market Size and Y-o-Y Growth
4.5.2 Acquired Orphan Blood Diseases Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Medication
5.2.2 Bone Marrow Transplant
5.2.3 Blood Transfusion
5.2.4 Immunotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acquired Orphan Blood Diseases Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acquired Orphan Blood Diseases Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Medication
9.6.2 Bone Marrow Transplant
9.6.3 Blood Transfusion
9.6.4 Immunotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Medication
10.6.2 Bone Marrow Transplant
10.6.3 Blood Transfusion
10.6.4 Immunotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Medication
11.6.2 Bone Marrow Transplant
11.6.3 Blood Transfusion
11.6.4 Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Medication
12.6.2 Bone Marrow Transplant
12.6.3 Blood Transfusion
12.6.4 Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Medication
13.6.2 Bone Marrow Transplant
13.6.3 Blood Transfusion
13.6.4 Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acquired Orphan Blood Diseases Therapeutics Market: Competitive Dashboard
14.2 Global Acquired Orphan Blood Diseases Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alexion Pharmaceuticals
14.3.2 Amgen
14.3.3 Celgene
14.3.4 Eli Lilly
14.3.5 Sanofi
14.3.6 GlaxoSmithKline
14.3.7 Cyclacel Pharmaceuticals
14.3.8 Onconova Therapeutics
14.3.9 Incyte
14.3.10 CTI BioPharma
